Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Innovative in-line Raman analytical sensor for new upstream cell culture monitoring and quality control

Objectif

The main objective of the CellUp business innovation project is to develop and commercialize the new disruptive in-line
analytics sensor for upstream cell culture process that the biopharmaceutical industry needs for the quality and process
control during the phases of process development, scale-up and manufacturing of vaccines and antibodies for human
medicines based on eukaryote cells culture.
This new bioprocess analyser will be the first industrial sensor able to perform in-line quantification of the main nutrients and
metabolites during the mammalian cell culture inside the bioreactor.
Today, cell cultures in bioreactors are only monitored in real time with temperature, PH and Oxygen density sensors. The
negative consequences of such a limited control are huge in terms of batch failures, time consumed at each scale-up phase
and in terms of untapped production yield improvement.
Our company, with its unique integrated SWIFTS technology has the opportunity to fix the above described problem by
offering a high performance miniaturized in-line Raman analyzer which can be implemented as an industrial GMP sensor.
Based on the needs expressed by several major industrial actors, the company has already developed a first product
successfully evaluated and released end of 2016 under the name ProCellics.
The objective of the CellUp project is to go a step further in the integration of the Raman analyser thanks to a new
configuration of our technology, called SWITS-CD. We will also develop a new “standard addition method” technology and a
related software to provide an easy and robust way to implement the monitoring of the cell culture. The key to the success of
this new methodology development is a cell culture activity carried internally by our company.
The total accessible market is estimated at 750 M€ for a first equipment of the 20,000 biopharma industry bioreactors, allowing the emergence of a European leader with more than 300 job creation over 10 years.

Appel à propositions

H2020-SMEInst-2016-2017

Voir d’autres projets de cet appel

Sous appel

H2020-SMEINST-2-2016-2017

Régime de financement

SME-2 - SME instrument phase 2

Coordinateur

RESOLUTION SPECTRA SYSTEMS
Contribution nette de l'UE
€ 1 969 553,75
Adresse
13 CHEMIN DU VIEUX CHENE
38240 MEYLAN
France

Voir sur la carte

PME

L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.

Oui
Région
Auvergne-Rhône-Alpes Rhône-Alpes Isère
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
€ 1 969 553,75